Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

BUY
$2.8 - $5.46 $302,411 - $589,701
108,004 New
108,004 $313,000
Q1 2022

May 16, 2022

BUY
$8.44 - $16.89 $69,722 - $139,528
8,261 Added 11.28%
81,523 $757,000
Q4 2021

Feb 14, 2022

BUY
$14.7 - $19.89 $779 - $1,054
53 Added 0.07%
73,262 $1.15 Million
Q3 2021

Nov 15, 2021

SELL
$11.99 - $17.9 $154,706 - $230,963
-12,903 Reduced 14.98%
73,209 $1.31 Million
Q2 2021

Aug 16, 2021

BUY
$12.89 - $16.58 $68,239 - $87,774
5,294 Added 6.55%
86,112 $1.34 Million
Q4 2020

Mar 01, 2021

BUY
$12.67 - $26.23 $257,644 - $533,387
20,335 Added 33.62%
80,818 $1.59 Million
Q3 2020

Nov 13, 2020

SELL
$11.92 - $15.87 $55,964 - $74,509
-4,695 Reduced 7.2%
60,483 $783,000
Q2 2020

Aug 14, 2020

BUY
$7.53 - $14.93 $45,292 - $89,803
6,015 Added 10.17%
65,178 $949,000
Q1 2020

May 15, 2020

BUY
$5.69 - $17.78 $80,536 - $251,658
14,154 Added 31.45%
59,163 $503,000
Q4 2019

Feb 14, 2020

SELL
$10.89 - $16.79 $3.41 Million - $5.25 Million
-312,841 Reduced 87.42%
45,009 $741,000
Q3 2019

Nov 14, 2019

BUY
$12.03 - $19.94 $1.08 Million - $1.8 Million
90,077 Added 33.64%
357,850 $5.05 Million
Q2 2019

Aug 15, 2019

BUY
$19.05 - $41.04 $777,163 - $1.67 Million
40,796 Added 17.97%
267,773 $0
Q1 2019

May 14, 2019

BUY
$28.4 - $41.74 $25,560 - $37,566
900 Added 0.4%
226,977 $0
Q4 2018

Feb 13, 2019

BUY
$30.9 - $42.97 $267,563 - $372,077
8,659 Added 3.98%
226,077 $7.85 Million
Q3 2018

Nov 14, 2018

SELL
$35.05 - $43.5 $534,091 - $662,853
-15,238 Reduced 6.55%
217,418 $0
Q2 2018

Aug 14, 2018

BUY
$35.15 - $51.45 $7.64 Million - $11.2 Million
217,362 Added 1421.22%
232,656 $0
Q1 2018

May 14, 2018

BUY
$18.0 - $48.35 $275,292 - $739,464
15,294 New
15,294 $0

Others Institutions Holding ATRA

About Atara Biotherapeutics, Inc.


  • Ticker ATRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,362,304
  • Market Cap $728M
  • Description
  • Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...
More about ATRA
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.